ArticleCureus2025
Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma on Dialysis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and Efficacy of Enfortumab Vedotin and Pembrolizumab in 2 Hemodialysis Patients with Metastatic Urothelial Carcinoma: A Case Series.Case reports in oncologyArticle
- Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, enfortumab vedotin has emerged as a promising treatment option for metastatic urothelial carcinoma. Although it does not require dosage adjustments in patients with renal failure, its safety and efficacy, particularly in those undergoing dialysis, remain unclear. We report a case of metastatic urothelial carcinoma in a patient undergoing hemodialysis who achieved a complete response to enfortumab vedotin therapy without severe adverse events. This complete response was maintained for two years without any severe complications. Our case demonstrates that enfortumab vedotin can be safely administered long-term to patients undergoing hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.